



How ESE works with industry

Objectivity and transparency are critical to carrying out ESE's mission and to maintaining the confidence of its members, the endocrine community and the public. As health and knowledge are highly valuable public benefits, it is of the utmost importance that they are delivered independently. A Code of Conduct covering both ethical principles and conduct is a necessary underpinning to achieve this, and ESE adheres to the Code of Conduct for Healthcare Professionals and Scientific Organisations in Europe set out by the Alliance for Biomedical Research in Europe Biomed Alliance Code of Conduct, of which ESE is a member – see [here](#). Adoption of this Code reinforces the core principles that help to maintain professional independence, objectivity and scientific integrity.

It is recognized that working with industry is essential to achieve ESE's mission, and there are clear benefits on both sides, but this must be accomplished without compromising our integrity.

Key principles governing how ESE work with industry are as follows:

1. Any activity must be in line with ESE's vision, mission and strategic aims – see [here](#).
2. All partnerships will be based on the principles of integrity and openness and will bring benefit to ESE through funding or through supporting ESE to achieve its vision and mission.
3. Any agreements entered into will not compromise the independent status of ESE.
4. ESE will work with members of the pharmaceutical industry to share knowledge and expertise, as appropriate.
5. Multi-sponsor activities will be sought where possible; however in certain circumstances ESE will accept single sponsorship for activities if it is deemed to be in the best interest of those affected by endocrine conditions, as long as the other principles are adhered to.
6. Editorial independence must be maintained so that ESE and its members are free to comment both positively and negatively about pharmaceutical companies and their products.
7. Industry will have no input into the development of ESE scientific, clinical or educational programmes, unless specifically requested for a valid reason.
8. ESE will not work with industry where promotion of a specific drug is required or demanded by the company (either explicitly or implicitly), and will not endorse any pharmaceutical products or services.
8. Conflicts of interest are always disclosed, recorded and where deemed appropriate the person declaring the conflict is not included in discussions/votes where the conflict is relevant.
9. Collaborations will comply with all relevant Code of Practices, including the Biomed Alliance Code of Conduct, EFPIA code and MedTech Code.

3 February 2019